REZENOPY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rezenopy, and when can generic versions of Rezenopy launch?
Rezenopy is a drug marketed by Scienture and is included in one NDA. There are two patents protecting this drug.
This drug has four patent family members in four countries.
The generic ingredient in REZENOPY is naloxone hydrochloride. There are twelve drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rezenopy
A generic version of REZENOPY was approved as naloxone hydrochloride by HOSPIRA on September 24th, 1986.
US Patents and Regulatory Information for REZENOPY
REZENOPY is protected by two US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scienture | REZENOPY | naloxone hydrochloride | SPRAY;NASAL | 215487-001 | Apr 19, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Scienture | REZENOPY | naloxone hydrochloride | SPRAY;NASAL | 215487-001 | Apr 19, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Scienture | REZENOPY | naloxone hydrochloride | SPRAY;NASAL | 215487-001 | Apr 19, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for REZENOPY
See the table below for patents covering REZENOPY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2021217164 | Drug products for intranasal administration and uses thereof | ⤷ Start Trial |
| Canada | 3166250 | PRODUITS MEDICAMENTEUX DESTINES A ETRE ADMINISTRES PAR VOIE INTRANASALE ET UTILISATIONS ASSOCIEES (DRUG PRODUCTS FOR INTRANASAL ADMINISTRATION AND USES THEREOF) | ⤷ Start Trial |
| European Patent Office | 4100012 | PRODUITS MÉDICAMENTEUX DESTINÉS À ÊTRE ADMINISTRÉS PAR VOIE INTRANASALE ET UTILISATIONS ASSOCIÉES (DRUG PRODUCTS FOR INTRANASAL ADMINISTRATION AND USES THEREOF) | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2021158957 | ⤷ Start Trial | |
| Australia | 2021217164 | ⤷ Start Trial | |
| Canada | 3166250 | ⤷ Start Trial | |
| European Patent Office | 4100012 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for REZENOPY
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1685839 | 92292 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch